SecBot SecBot
PRESS-RELEASE ·Filed Mar 10, 2026

BNTX

BioNTech SE
BEARISH
Impact 7/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

Traders should monitor upcoming 2026 clinical readouts (e.g., pumitamig, gotistobart, trastuzumab pamirtecan) as key value drivers, but anticipate continued revenue contraction and losses in the near term. The management transition adds execution risk; any delays in oncology pipeline milestones could pressure the stock further.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$83.89
T+0 close · Mar 10, 2026 · via day close
Latest settled
+5.44%
T+60 · $88.45
Vs SPY
−6.25%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 10 $83.89entry
  2. T+1 · 8mo ago +8.28%α +8.39% · $90.84
  3. T+5 · 8mo ago +13.08%α +13.98% · $94.86
  4. T+20 · 7mo ago +9.76%α +9.92% · $92.08
  5. T+60 · 6mo ago +5.44%α −6.25% · $88.45
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech reported full-year 2025 revenues of €2.87 billion, up 4.3% YoY, but posted a net loss of €1.14 billion (€4.70 diluted loss per share), widening from a €665.3 million loss in 2024. The quarterly revenue declined 23.7% due to lower COVID-19 vaccine demand, and the company issued 2026 revenue guidance of €2.0–2.3 billion, signaling a further decline. Despite a strong cash position of €17.2 billion, the outlook reflects continued transition from pandemic-era revenues to oncology-focused R&D, with multiple late-stage readouts expected in 2026.

Key Financial Metrics

Revenue
$2.9B
+4.3% YoY
Adj. EPS
$-0.48
GAAP: $-4.70
Guidance
€2.0B–€2.3B
lowered

Key Facts

  • Full-year 2025 revenue: €2.87 billion (up 4.3% YoY), driven by BMS collaboration revenue in Q3
  • Q4 2025 revenue: €907.4 million, down 23.7% YoY due to lower COVID-19 vaccine demand
  • Full-year 2025 net loss: €1.14 billion, compared to €665.3 million loss in 2024
  • 2026 revenue guidance: €2.0–2.3 billion, implying 19.7%–20.8% YoY decline at midpoint
  • Co-founders Ugur Sahin and Özlem Türeci to leave by end of 2026 to lead a new independent mRNA company
  • Cash, cash equivalents, and security investments: €17.2 billion as of Dec 31, 2025

Financial Impact

Revenue expected to decline by ~20% in 2026; adjusted R&D expenses to increase to €2.2–2.5 billion despite falling topline

revenuenet lossepsr&d expensessg&a expenses

Risk Factors

  • Declining revenue and widening losses despite cost discipline
  • Management transition risk with co-founders departing by 2026
  • Heavy reliance on upcoming clinical data readouts for valuation support
  • 2026 guidance implies continued erosion of core vaccine business without near-term commercial offsets

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3252585

Track record

38 reports on BNTX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 15 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 10, 2026